Lieke H. van der Helm

Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes

G. Ossenkoppele, C. Eeltink, A. A. van de Loosdrecht, 2014, Cytometry. Part B, Clinical cytometry.

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme

E. Vellenga, B. Biemond, A. A. van de Loosdrecht, 2011, British journal of haematology.